UNCY Earnings & Financial Statements
Unicycive Therapeutics, Inc.
$3.70
-$0.03(-0.80%)
36
Overall
55
Value
36
Tech
18
Quality
Market Cap
$103.06M
Volume
1.20M
52W Range
$3.93 - $8.74
Target Price
$26.89
UNCY earnings and financial statements: Unicycive Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
UNCY Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $675.0K | $951.0K | - |
| Operating income | -$29.52M | -$32.12M | -$20.77M | -$18.05M | -$8.98M |
| EBITDA | -$25.95M | -$36.23M | -$30.26M | -$17.89M | -$8.46M |
| Net income | -$26.55M | -$36.73M | -$30.54M | -$18.06M | -$10.02M |
| EPS (diluted) | $-1.67 | $-5.60 | $-12.80 | $-12.00 | $-8.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $49.13M | $31.67M | $14.19M | $2.82M | $18.74M |
| Total liabilities | $18.94M | $24.24M | $18.00M | $3.28M | $2.26M |
| Shareholders’ equity | $30.20M | $7.43M | -$3.81M | -$466.0K | $16.48M |
| Cash and equivalents | $29.20M | $26.14M | $9.70M | $455.0K | $16.58M |
| Long-term debt | - | $117.0K | $466.0K | - | $155.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$31.32M | -$28.57M | -$18.28M | -$15.65M | -$5.77M |
| Capital expenditure | -$24.0K | -$72.0K | -$12.0K | -$2.0K | -$29.0K |
| Free cash flow | -$31.34M | -$28.65M | -$18.30M | -$15.65M | -$5.80M |
| Dividends paid | - | $1.09M | - | - | - |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | UNCY | $3.70 | -0.8% | 1.20M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Unicycive Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW